Noopur Raje, MD
The deep and durable responses observed with the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy bb2121 suggest that the novel treatment could be a significant addition to the armamentarium, according to Noopur Raje, MD.
, Raje, director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discussed the latest treatment advances in multiple myeloma.
OncLive: Do you have any update for the ongoing phase II study with bb2121?
: We have seen the phase I data, which were recently presented. These data obviously looked very promising, which is what prompted the phase II study. We haven't seen any data yet from the phase II study, but I know that it's rapidly accruing. The trial started accruing only at the beginning of this year, and we're almost halfway through completely accruing for this trial. The hope is that we will meet our goal before the end of the year. As far as efficacy, we'll just have to wait and see.
What impact could bb2121 have on the treatment landscape?
It [would be] a really important addition to the armamentarium we already have. Given that we're seeing stringent responses in patients who are MRD negative—which we would have never expected to see in a patient population that was as refractory as it was in the phase I trial—it's really encouraging. The fact that we're seeing a PFS of close to 1 year in this heavily pretreated penta-refractory patient population with more than 7 prior lines of treatment—it's not what we imagined. For us to also have seen not that much toxicity was actually really reassuring. We're seeing patients who were MRD negative with a PFS of more than 17 months. These data are really incredible. We're all very excited.
... to read the full story